期刊文献+

阿托伐他汀不良反应及合理应用 被引量:22

Adverse Drug Reactions Caused by Atorvastatin and Clinical Rational Use
下载PDF
导出
摘要 目的对临床一线调脂药阿托伐他汀所致药品不良反应(ADR)进行分析,为临床合理用药提供参考。方法文献检索2001年6月—2011年6月国内医药期刊报道的有关阿托伐他汀的不良反应案例,共收集34例,进行统计分析和归纳。结果 34例不良反应临床表现以肌损害最常见(47.06%),其次是肝-胆异常(29.41%),老年患者(≥61岁)发生率较高(64.71%)。结论多种药物合用是导致阿托伐他汀不良反应的重要危险因素。提示应注意药物相互作用,加强用药监测,以减少或避免ADR的发生。 Objective To analyze the adverse drug reactions(ADR) caused by atorvastatin to offer the references for clinical rational use.Methods 34 cases of ADR induced by atorvastatin reported in domestic medical journals duing the period of 2001.6~2011.6,And statistical analysis was made.Results In 34 cases of ADR,Muscular damage was the commom clinical manifestation(47.06%),Followed by liver and biliary abnormal(29.41%),The risk factors of highter incidence rate were elderly pations(≥61 years old).Conclusion The drug combination are very important risk factors of ADR caused by atorvastatin.It is suggested that attention to drug interaction and strengthen medication monitoring to reduce or avoid the recurrence of ADR.
作者 陈雪梅
出处 《临床合理用药杂志》 2012年第3期32-33,共2页 Chinese Journal of Clinical Rational Drug Use
关键词 阿托伐他汀 不良反应 合理用药 Atorvastatin Adverse drug reactions Rational drug use
  • 相关文献

参考文献5

二级参考文献47

  • 1由春娜,芮伟,翟所迪.他汀类药物安全性及其在特定疾病人群中的应用[J].世界临床药物,2004,25(10):611-617. 被引量:7
  • 2邱国应.他汀类药物的临床应用新进展[J].中国心血管病研究,2006,4(8):638-640. 被引量:16
  • 3Steven E. Nissen,Stephen J. Nicholls,Ilks Sipahi,Peter Libby,Joel S. Raichlen,Christie M. Ballantyne,Jean Davignon,Raimund Erbel,Jean Charles Fruchart,Jean-Claude Tardif,Paul Schoenhagen,Tim Crowe,Valerie Cain,Kathy Wolski,Marlene Coormastic,E. Murat Tuzcu,仝其广(译),王淑敏(译),胡大一(校).极高强度他汀治疗对冠状动脉粥样硬化消退的影响——ASTEROID试验[J].美国医学会杂志(中文版),2006,25(4):215-223. 被引量:348
  • 4Rosuvastatin Registration Clinical Trial Group.Cardiovascular Institute and Fu Wai Hospital,Peking Union Medical College and Chinese Academy of Medical Science,Beijing 100037,China.瑞舒伐他汀治疗中国高胆固醇血症患者疗效和安全性的随机双盲多中心对照研究[J].中华心血管病杂志,2007,35(3):207-211. 被引量:117
  • 5张红,熊玉卿.单次口服瑞舒伐他汀钙片在中国健康志愿者的药代动力学[J].中国临床药理学杂志,2007,23(4):268-271. 被引量:13
  • 6Sever PS,Dahl of B,Poulter NR,et al.Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentration,in the angi o-scandinavian carsdic outcomes trial-lipid-lowering arm (ASCOT-LLA):a multicentre randomized controlled trial[J].Lancet,2003,361:1149-2258.
  • 7Mellors A,Tappel A L.The inhibition of mitochondrial peroxidation by ubiquinone and ubiquinol[J].J Biol Chern,1966,241:4353-4356.
  • 8Moride Y,Hegele RA,Langer A,et al.Clinical and public health assessment of benefits and risks of statins in primary prevention of coronary events:resolved and unresolved issue[J].Can J Cardiol,2008,24 (4):293-300.
  • 9Vasa M,Fichtlscheres S.Increaes in circulating endothelial progenitor cells by statin therapy in patients with stable cororary artery disease[J].Circulation,2001,103 (9):2885-2890.
  • 10Amorose G,Van Veldhuisen DJ,Tio RA,et al.Pathophysiology of vascular endothelium and circulation platelets:Implications for coronary revasculavisation and treatmet[J].Int J Cardiol,2001,79(223):265-275.

共引文献59

同被引文献209

引证文献22

二级引证文献100

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部